Researchers have found that levels of methylated microRNA were significantly higher in tissue and serum from cancer patients compared with that from normal controls. Specifically, methylation levels in serum samples distinguished patients with early pancreatic cancer from healthy controls with extremely high sensitivity and specificity. These findings provide a basis for new diagnostic strategies for early-stage cancer and represent a new perspective for understanding microRNA biology.